P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions.

Gragnano, Felice; Mehran, Roxana; Branca, Mattia; Franzone, Anna; Baber, Usman; Jang, Yangsoo; Kimura, Takeshi; Hahn, Joo-Yong; Zhao, Qiang; Windecker, Stephan; Gibson, Charles M; Kim, Byeong-Keuk; Watanabe, Hirotoshi; Song, Young Bin; Zhu, Yunpeng; Vranckx, Pascal; Mehta, Shamir; Hong, Sung-Jin; Ando, Kenji; Gwon, Hyeon-Cheol; ... (2023). P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions. Journal of the American College of Cardiology, 81(6), pp. 537-552. Elsevier 10.1016/j.jacc.2022.11.041

[img] Text
1-s2.0-S0735109722075520-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB)

BACKGROUND

It remains unclear whether P2Y12 inhibitor monotherapy preserves ischemic protection while limiting bleeding risk compared with dual antiplatelet therapy (DAPT) after complex percutaneous coronary intervention (PCI).

OBJECTIVES

We sought to assess the effects of P2Y12 inhibitor monotherapy after 1-month to 3-month DAPT vs standard DAPT in relation to PCI complexity.

METHODS

We pooled patient-level data from randomized controlled trials comparing P2Y12 inhibitor monotherapy and standard DAPT on centrally adjudicated outcomes after coronary revascularization. Complex PCI was defined as any of 6 criteria: 3 vessels treated, ≥3 stents implanted, ≥3 lesions treated, bifurcation with 2 stents implanted, total stent length >60 mm, or chronic total occlusion. The primary efficacy endpoint was all-cause mortality, myocardial infarction, and stroke. The key safety endpoint was Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding.

RESULTS

Of 22,941 patients undergoing PCI from 5 trials, 4,685 (20.4%) with complex PCI had higher rates of ischemic events. The primary efficacy endpoint was similar between P2Y12 inhibitor monotherapy and DAPT among patients with complex PCI (HR: 0.87; 95% CI: 0.64-1.19) and noncomplex PCI (HR: 0.91; 95% CI: 0.76-1.09; Pinteraction = 0.770). The treatment effect was consistent across all the components of the complex PCI definition. Compared with DAPT, P2Y12 inhibitor monotherapy consistently reduced BARC 3 or 5 bleeding in complex PCI (HR: 0.51; 95% CI: 0.31-0.84) and noncomplex PCI patients (HR: 0.49; 95% CI: 0.37-0.64; Pinteraction = 0.920).

CONCLUSIONS

P2Y12 inhibitor monotherapy after 1-month to 3-month DAPT was associated with similar rates of fatal and ischemic events and lower risk of major bleeding compared with standard DAPT, irrespective of PCI complexity. (PROSPERO [P2Y12 Inhibitor Monotherapy Versus Standard Dual Antiplatelet Therapy After Coronary Revascularization: Individual Patient Data Meta-Analysis of Randomized Trials]; CRD42020176853).

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology
04 Faculty of Medicine > Pre-clinic Human Medicine > Department of Clinical Research (DCR)

UniBE Contributor:

Branca, Mattia, Windecker, Stephan, Heg, Dierik Hans, Valgimigli, Marco

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0735-1097

Publisher:

Elsevier

Language:

English

Submitter:

Pubmed Import

Date Deposited:

09 Feb 2023 09:39

Last Modified:

20 Feb 2024 14:15

Publisher DOI:

10.1016/j.jacc.2022.11.041

PubMed ID:

36754514

Uncontrolled Keywords:

DAPT P2Y(12) inhibitors complex PCI meta-analysis percutaneous coronary intervention

BORIS DOI:

10.48350/178564

URI:

https://boris.unibe.ch/id/eprint/178564

Actions (login required)

Edit item Edit item
Provide Feedback